Cargando…

Reporting Extended-Spectrum β-Lactamase Positivity May Reduce Carbapenem Overuse

Detalles Bibliográficos
Autores principales:	Tamma, Pranita D, Cosgrove, Sara E, Avdic, Edina, Carroll, Karen C, Simner, Patricia J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419984/ https://www.ncbi.nlm.nih.gov/pubmed/30895204 http://dx.doi.org/10.1093/ofid/ofz064

Ejemplares similares

The Frequency of Extended-Spectrum β-Lactamase Genes Harbored by Enterobacterales Isolates at High Risk for Clinically Significant Chromosomal ampC Expression
por: Hareza, Dariusz, et al.
Publicado: (2023)

716 Risk Factors for Resistance to Beta-lactam/Beta-lactamase Inhibitors and Carbapenems in Bacteroides spp. Bacteremia
por: Smith, Janessa, et al.
Publicado: (2014)

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
por: Wang, Ruibin, et al.
Publicado: (2016)

2487. Which Extended-Spectrum β-Lactamase-Producing Enterobacterales Colonize the Gastrointestinal Tract of High-Risk Patients?
por: Stambaugh, Haley, et al.
Publicado: (2023)

Impact of PBP2a Assay on Antibiotic Therapy of Patients with Non-Blood, Non-Urine Staphylococcus aureus Infections
por: Shulder, Stephanie, et al.
Publicado: (2017)

Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection
por: Castanheira, Mariana, et al.
Publicado: (2021)

Prevent Antibiotic overUSE (PAUSE): Impact of a Provider Driven Antibiotic-Time out on Antibiotic Use and Prescribing
por: Thom, Kerri, et al.
Publicado: (2017)

The Role of Ertapenem for the Treatment of Complicated Intra-abdominal Infections With a Positive Culture for Enterococcus faecalis
por: Fabre, Valeria, et al.
Publicado: (2018)

2253. Comparison of Outcomes Between Patients with and without Cystic Fibrosis Treated with Ceftolozane–Tazobactam for Pseudomonas aeruginosa Infections
por: Trisler, Michael J, et al.
Publicado: (2019)

Using Patient Risk Factors to Identify Whether Carbapenem-Resistant Enterobacteriaceae Infections Are Caused by Carbapenemase-Producing Organisms
por: Simner, Patricia J, et al.
Publicado: (2018)

Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance
por: Rudresh, S.M., et al.
Publicado: (2011)

52. Development and Implementation of a Short Duration of Antibiotic Therapy Algorithm for Uncomplicated Gram-Negative Bacteremia
por: Bae, Esther Y, et al.
Publicado: (2020)

Extended-spectrum β-lactamase producing Klebsiella pneumoniae from blood cultures in Puducherry, India
por: Parveen, R.M., et al.
Publicado: (2011)

Risk factors for colonization with multiple species of extended-spectrum beta-lactamase producing Enterobacterales: a case-case–control study
por: Vock, Isabelle, et al.
Publicado: (2021)

1452. Is Carbapenem-Sparing Therapy as Effective as Carbapenems Against Extended-Spectrum β-Lactamase Producing Enterobacteriaceae in UTI?
por: Hyun, Jonghoon, et al.
Publicado: (2019)

Performance of extended spectrum beta lactamases (ESBL) screening agar in various clinical specimens
por: Swarna, S.R., et al.
Publicado: (2015)

Independent, external validation of clinical prediction rules for the identification of extended-spectrum β-lactamase-producing Enterobacterales, University Hospital Basel, Switzerland, January 2010 to December 2016
por: Vock, Isabelle, et al.
Publicado: (2020)

1588. Clinical Prediction Tool for Extended-Spectrum Β Lactamase-Producing Enterobacteriaceae as the Etiology of Bacteremia in Solid Organ Transplant Recipients
por: Wang, Rebecca, et al.
Publicado: (2018)

Multicentre genetic diversity study of carbapenem-resistant Enterobacterales: predominance of untypeable pUVA-like bla(KPC) bearing plasmids
por: Simner, Patricia J, et al.
Publicado: (2023)

1055. Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum β-Lactamase- Producing Enterobacteriaceae Bacteremia
por: Aitken, Samuel L, et al.
Publicado: (2018)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
por: Gibble, Allison M., et al.
Publicado: (2015)

Extended-Spectrum Beta-Lactamase and Carbapenem-Resistant Gram-Negative Pathogens in Makkah, Saudi Arabia
por: Kabrah, Ahmed
Publicado: (2022)

Extended-spectrum β-lactamase & carbapenemase-producing Gram-negative bacilli in neonates from a tertiary care centre in Dibrugarh, Assam, India
por: Devi, Utpala, et al.
Publicado: (2018)

Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae
por: Viale, Pierluigi, et al.
Publicado: (2015)

Efficacy of Noncarbapenem β-Lactams Compared to Carbapenems for Extended-Spectrum β-Lactamase–Producing Enterobacterales Urinary Tract Infections
por: Anderson, Daniel T, et al.
Publicado: (2022)

Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens
por: Banerjee, Sayantan, et al.
Publicado: (2017)

Extended-Spectrum Beta-Lactamase-Producing and Carbapenem-Resistant Enterobacterales in Companion and Animal-Assisted Interventions Dogs
por: Roscetto, Emanuela, et al.
Publicado: (2021)

Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae
por: Katip, Wasan, et al.
Publicado: (2021)

Epidemiology of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacterales in US children, 2016–2020
por: Grome, Heather, et al.
Publicado: (2023)

Prevalence of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana
por: Sampah, James, et al.
Publicado: (2023)

211. Disease burden of bacteremia with extended-spectrum beta-lactamase-producing or carbapenem-resistant Enterobacteriaceae in Korea
por: Mi Lee, Chan, et al.
Publicado: (2023)

2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
por: Hefler, Jade L, et al.
Publicado: (2019)

Community Transmission of Extended-Spectrum β-Lactamase
por: Mirelis, Beatriz, et al.
Publicado: (2003)

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)

Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems
por: Walker, Kristy J., et al.
Publicado: (2018)

838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
por: Stone, Tyler J, et al.
Publicado: (2020)

Prevalence of extended-spectrum β-lactamase positive bacteria in radiologically positive urinary tract infection
por: Masud, Md Rana, et al.
Publicado: (2014)

To Use, or Not to Use Carbapenem When Extended-spectrum β-lactamase (ESBL)-producing Bacteria Are Isolated from Sputum Cultures, That Is the Question
por: Miki, Makoto
Publicado: (2017)

Emergence of Colistin and Carbapenem Resistance in Extended-Spectrum β-Lactamase Producing Klebsiella pneumoniae Isolated from Chickens and Humans in Egypt
por: Elmonir, Walid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_arbpm195n17qii5qnllapn4hv7